In today’s briefing:
- SHEIN (希音) Pre-IPO: Forecast and Valuation
- Lenovo Q1 FY26/27. Key Takeaways & Full Earnings Call Transcript
- Modern Dental Group (3600 HK): Synthetic Expert Call Transcript (14 Aug 2026)
- IPO Databook: Suzhou Zelgen Biopharmaceuticals (HK) – Aug 2026
- Hangzhou CIEC Group (CIEC HK): Synthetic Expert Call Transcript (14 Aug 2026)
SHEIN (希音) Pre-IPO: Forecast and Valuation
- SHEIN, a global online fashion and lifestyle retailer, has passed the HKEX listing hearing. GS, MS and JPM are joint sponsors.
- In our previous notes, we looked at the company’s business and financials and compared it with listed peers.
- In this note, we forecast earnings and provide our thoughts on valuation.
Lenovo Q1 FY26/27. Key Takeaways & Full Earnings Call Transcript
- Lenovo (HKSE: 992) reported first-quarter fiscal 2026/27 results with revenues reaching an all-time quarterly high of US$26.9 billion, up 43% YoY, and up 25% QoQ
- Adjusted net income, jumped 176% YoY to US$1.075 billion, crossing the US$1 billion milestone for the first time ever.
- Earlier, the company communicated that they want to achieve $100 billion yearly revenue in two years. With the strong momentum in Q1, they are now ahead of that schedule.
Modern Dental Group (3600 HK): Synthetic Expert Call Transcript (14 Aug 2026)
- Organic Growth vs. Inflation: True organic volume expansion is concentrated in the European and Australian markets, while North America and Greater China have historically experienced volume contraction. Revenue growth is highly exchange-rate-sensitive, particularly concerning the Euro and Australian Dollar appreciating against the Renminbi and Hong Kong Dollar.
- MicroDental Underperformance: The North American division, MicroDental, has consistently failed to meet initial synergy targets, with core operating profit dropping from HK$16.67 million in 2023 to HK$7.48 million in 2024. This prompted a hard pivot toward closing inefficient labs, relocating production offshore, and weeding out low-margin economy lines to defend group-level gross margins.
- Defending Against In-Sourcing & Chairside: Modern Dental Group is combatting the threat of in-office “chairside” milling and 3D printing by moving up the value chain into complex restorations (such as multi-unit bridges and implant abutments) that chairside systems cannot replicate. Simultaneously, the company is positioning itself as a key supplier of clinical design services, software, and materials (via partnerships like SprintRay) to capture revenue even when production moves in-house.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
IPO Databook: Suzhou Zelgen Biopharmaceuticals (HK) – Aug 2026
- Suzhou Zelgen Biopharmaceuticals is an integrated biopharmaceutical company focused on oncology, autoimmune diseases, and hemostasis/hematology, powered by a dual innovation engine.
- The company has four commercialized drugs, including Zepsun® and Zepuping, and a pipeline of 10 drug candidates across 29 clinical programs.
- Revenue was RMB1,204,390 thousand and net profit RMB640,010 thousand for the six months ended June 30, 2026.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Hangzhou CIEC Group (CIEC HK): Synthetic Expert Call Transcript (14 Aug 2026)
- Hangzhou CIEC’s IPO is driven by severe liquidity and working capital pressures, as evidenced by its massive operating cash flow deficit of -RMB 4.82 billion in 2025 and -RMB 2.27 billion in the first five months of 2026. The urgent August 11, 2026 HKEX refiling—just days after the initial February application lapsed—highlights the immediate need to unlock offshore credit lines.
- The reported gross margins of 0.6% in 2025 are highly deceptive because the company’s core business relies on basis trading (基差交易). While physical transactions are recorded at razor-thin margins, the true economic spread is captured in the derivative books, which yielded RMB 2.08 billion in 2025 but swung to a RMB 584 million loss in early 2026 due to extreme commodity price volatility.
- The company’s risk management and hedging framework is under severe strain, as highlighted by the RMB 170.5 million foreign exchange loss in 2025 and a further RMB 151.5 million loss in the first five months of 2026. High leverage (asset-liability ratio of 81.74% as of May 2026) and a massive inventory buildup of RMB 23.20 billion as of June 12, 2026, expose the company to significant market downcycles.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
